Group by Gene: Include preclinical: CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy Chemotherapy BCL Inhibitors DNA EGFR Tyrosine Kinase Inhibitors Serine-Threonine Kinase Inhibitors | PD1 inhibitor pembrolizumab | cemiplimab-rwlc | Thymidylate synthase inhibitor capecitabine | 5-fluorouracil | DNA synthesis inhibitor cisplatin | Tubulin polymerization promoter, Bcl2 inhibitor carboplatin + paclitaxel | EGFR inhibitor cetuximab | Tubulin polymerization promoter carboplatin | PD1 inhibitor, EGFR inhibitor pembrolizumab + panitumumab | TLR7 agonist, TLR8 agonist imiquimod | DNA synthesis inhibitor, Thymidylate synthase inhibitor cisplatin + 5-fluorouracil | HER2 inhibitor, PD1 inhibitor, EGFR inhibitor nivolumab + lapatinib | mTOR inhibitor everolimus |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No biomarker | |||||||||||||
PD-L1 expression | |||||||||||||
TMB-H + PD-L1 expression | |||||||||||||
TMB-H | |||||||||||||
MSH6 mutation + MLH1 mutation + MSI-H | |||||||||||||
SRC amplification | |||||||||||||
TP53 mutation | |||||||||||||
BRCA2 deletion | |||||||||||||
ERBB3 R135C + TMB-H | |||||||||||||
NGFR overexpression | |||||||||||||
CCND1 overexpression |